Monte Rosa Therapeutics (GLUE) Non-Current Deferred Tax Liability (2024)
Monte Rosa Therapeutics' (GLUE) quarterly Non-Current Deferred Tax Liability came in at $11.5 million in Q4 2024.
Monte Rosa Therapeutics (GLUE) Non-Current Deferred Tax Liability (2024) Analysis & Trends
Monte Rosa Therapeutics' Non-Current Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $11.5 million for Q4 2024.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $11.5 million in Q4 2024; TTM through Dec 2024 was $11.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $11.5 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability steadied at $11.5 million in Q4 2024 per GLUE's latest filing.
- Across five years, Non-Current Deferred Tax Liability topped out at $11.5 million in Q4 2024 and bottomed at $11.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 11.50 Mn |
| Dec 31, 2024 | 11.50 Mn |